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Abstract Mucolipidosis II (ML II or I-cell disease)
(OMIM 252500) is an autosomal recessive lysosomal
enzyme targeting disorder that usually presents between
6 and 12 months of age with a clinical phenotype
resembling Hurler syndrome and a radiological picture
of dysostosis multiplex. When ML II is severe enough to
be detected in the newborn period, the radiological
changes have been described as similar to hyperpara-
thyroidism or rickets. The biological basis of these
ﬁndings has not been explored and few biochemical
measurements have been recorded. We describe three
unrelated infants with ML II who had radiological fea-
tures of intrauterine hyperparathyroidism and bio-
chemical ﬁndings consistent with severe secondary
neonatal hyperparathyroidism (marked elevation of
serum parathyroid hormone and alkaline phosphatase
levels). The vitamin D metabolites were not substantially
diﬀerent from normal and repeatedly normal calcium
concentrations excluded vitamin D deﬁciency rickets
and neonatal severe hyperparathyroidism secondary to
calcium-sensing receptor gene mutations (OMIM
239200). The pathogenesis of severe hyperparathyroid-
ism in the fetus and newborn with ML II is unexplained.
We hypothesize that the enzyme targeting defect of ML
II interferes with transplacental calcium transport lead-
ing to a calcium starved fetus and activation of the
parathyroid response to maintain extracellular calcium
concentrations within the normal range. Conclusion:
Newborns with mucolipidosis II can present with
radiological and biochemical signs of hyperparathy-
roidism. Awareness of this phenomenon may help in
avoiding diagnostic pitfalls and establishing a proper
diagnosis and therapy.
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Introduction
Mucolipidosis II (ML II), or I-cell disease (OMIM
252500), is a rare storage disorder resulting from a defect
in the localisation of lysosomal enzymes into the lyso-
somes. Normally, nascent lysosomal enzymes in the
endoplasmic reticulum are recognised by their mannose-
6-phosphate residues in the N-linked carbohydrate side-
chains, directing them to the lysosomal compartment. In
ML II, the enzyme catalysing the addition of mannose-
6-phosphate to the polyantennary carbohydrate side-
chains is deﬁcient, leading to increased release of enzyme
into the extracellular medium at the expense of the
lysosomal compartment [27]. ML II was ﬁrst recognised
as a distinct entity in 1967 and was described as a
Hurler-like disorder [16]. However, it has a more severe
phenotype than Hurler disease with marked skeletal
dysplasia, signiﬁcant psychomotor retardation, and
death within the ﬁrst decade of life [17,20]. The diagnosis
of ML II is most often made in the second half of the 1st
year of life as the facial features coarsen, the growth
failure becomes more evident, and developmental con-
cerns are noted [20]. The diagnosis is established by
detection of multiple elevations in serum lysosomal en-
zyme activities and/or low activity in ﬁbroblasts. Under
light microscopy, characteristic inclusions are observed
in cultured ﬁbroblasts. Following the diagnosis, non-
speciﬁc neonatal features of the disease are often
recognised in retrospect. These include congenital hip
dislocation, club foot, inguinal hernia, gingival hyper-
trophy and small birth weight or birth length [3,17].
In the ﬁrst description of an ML II patient cohort, it
was noted that striking periosteal new bone formation
(‘‘cloaking’’ of the long bones) may be seen on newborn
X-ray ﬁlms, but it gradually resolves. The aetiology of
this early disturbance in bone mineral balance was not
further explored [17]. Several authors have since docu-
mented an ‘‘early stage’’ of bone changes in ML II that
precedes the development of typical dysostosis multiplex
[7, 15, 22,32]. These abnormalities have been variously
described as sub-periosteal resorption, rickets-like, or
cloaking. The skeleton is osteopenic and some infants
with frank fractures were initially diagnosed as lethal
osteogenesis imperfecta [3,32]. In 1989, Pazzaglia et al.
described a child with ML II who died at 5 months of
age with biochemical evidence of hyperparathyroidism
(elevated parathyroid hormone (PTH) and elevated
alkaline phosphatase (ALP) but low-to-normal serum
calcium and phosphate with increased urinary phos-
phate). Histological examination of bone at autopsy
revealed changes consistent with hyperparathyroidism
[24]. Further evidence that the disease is associated with
a true disturbance in mineral metabolism comes from
the report of a child with ML II who was detected as
having an osteopenic bone dysplasia in utero and sub-
sequently received vitamin D supplementation for the
1st year of life [22]. In that child, the radiological fea-
tures of metabolic bone disease resolved more quickly
than in another infant who was untreated. The authors
speculated that ML II perturbs vitamin D metabolism in
the maternal environment [22].
We present three further cases of ML II complicated
by prenatal onset hyperparathyrodism. Our observa-
tions suggest that the hyperparathyroidism is secondary
to a defect in fetal importation of calcium.
Case reports
Case 1
This child was born at 35.5 weeks gestation following an
uneventful pregnancy. The mother was a 29-year-old G3
P1 SA (spontaneous abortion)1 woman who had one
healthy daughter. A single antenatal ultrasound done at
18 weeks was reportedly normal. At birth, the proband
was noted to be small for gestational age with a birth
weight of 1.99 kg (10th percentile), birth length of
approximately 43 cm (10th percentile) and a head cir-
cumference of 30 cm (10th percentile). Her Apgar scores
were 5 at 1 min and 8 at 5 min. She had moderate
respiratory distress requiring supplemental oxygen but
was not intubated, and a chest X-ray ﬁlm revealed
irregular and osteopenic ribs. The child was subse-
quently referred to the Hospital for Sick Children for
further evaluation. The infant appeared wasted and
unwell and the gums were hypertrophied (Fig. 1).
Although the limbs were generally proportionate, the
left leg was bent and foreshortened. The ribs were easily
palpable and nodular. The X-ray ﬁlms showed dramatic
osteopenia and shortening of the long bones. There was
an appearance of ‘‘bone cloaked in bone’’ and expanded
metaphyses (Fig. 2).
Fig. 1 Photograph of case 1 taken on day 2 and shows the
hypertrophied gums typical of ML II
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On day 2 of life, the total serum calcium was
2.24 mmol/l (reference range 2.12–2.62 mmol/l) and
the ionised calcium 1.16 mmol/l (reference range
1.14–1.29 mmol/l). On day 4 of life, the phosphate was
1.12 mmol/l (reference range 1.30–2.20 mmol/l), and the
ALP was 711 U/l (reference range 185–555 IU/l). On
further investigation, the serum PTH was also elevated,
measuring 471 ng/l on day 10 of life (reference range
10–65 ng/l) and peaking at 1178 ng/l at 2 weeks of age.
On day 10, serum 25-hydroxyvitamin D (25OHD) was
18 nmol/l (reference range 25–90 nmol/l) and 1,25-di-
hydroxyvitamin D (1,25D) was 100 pmol/l (reference
range 40–140 pmol/l). In a maternal blood sample, the
following serum parameters were normal: calcium
(2.16 mmol/l), phosphate (1.42 mmol/l), ALP (131 IU/l;
reference range 25–100 IU/l in adults), PTH (52 ng/l),
25OHD (47 nmol/l) and 1,25D (51 pmol/l).
Over the course of the ﬁrst 3 months of life, she was
treated with vitamin D and calcium supplementation.
Her metabolic bone disease resolved both biochemically
(Fig. 3) and radiologically (Fig. 4). The PTH normalised
by 1 month of age and the ALP levels followed a similar
Fig. 3 Time course of vitamin
D treatment and changing
calcium metabolism in case 1.
Shown on this graph are serum
PTH, phosphate, and total
serum calcium values for the
ﬁrst few months of life. At the
time vitamin D and calcium
supplements were started (day
12), serum 25(OH)D and
1,25(OH)2D concentrations
(top of ﬁgure) were consistent
with reported reference values
(mean ± SD) for preterm
newborns (33±11 nmol/l and
56±33 pmol/, respectively)
[29]. Phosphate supplements
were started on day 32, after the
level dropped to 0.77. Urine
studies done on day 25 had
shown that there was no
urinary loss of phosphate,
glucose, amino acids or protein
Fig. 2 X-ray ﬁlm of the left humerus of case 1 on day 4 showing
osteopenia and cloaking as well as expansion at the proximal
metaphysis. Note also the poor cortical delineation of the lateral
aspect of the scapula
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but delayed course. However, the child continued to be
unwell and her facial features coarsened. The diagnosis
of ML II was conﬁrmed by assay of enzymes in serum:
arylsulfatase A 114 nmol/h per mg of protein (reference
range 21–72 nmol/h/mg protein) and total hexosamini-
dase 64180 nmol/h per ml (reference range 2350–
2450 nmol/h/ml). The radiological changes, in particular
the ribs, evolved into typical dysostosis multiplex
(Fig. 5). She suﬀered recurrent aspiration pneumonias
and died at 5 months of age.
Case 2
This patient was born at 36.5 weeks to an 18-year-old
G1P0 mother. The parents were ﬁrst cousins of Paki-
stani origin. The pregnancy had been complicated by
oligohydramnios and poor growth. Following the onset
of preterm labour, the child was delivered by caesarean
section for breech presentation. He was noted to be
small for gestational age with a birth weight of 2.1 kg
(<10th percentile), head circumference of 31.5 cm (10th
percentile) and a birth length of 43 cm (<10th percen-
tile). The patient also had bilateral inguinal hernias and
club feet. He had poor respiratory eﬀort at birth and
brieﬂy required positive pressure ventilation. His Apgar
scores were 5 at 5 min and 9 at 10 min. He was trans-
ferred to Johns Hopkins Hospital at 1 week of life for
further investigation and treatment.
Skeletal survey at 2 weeks of age revealed generalised
osteopenia with some bones being barely visible. There
was fraying and expansion of all metaphyses and stip-
pling was noted in both tarsal areas (Fig. 6). A calcium
level done that day was normal at 2.38 mmol/l as was
the phosphate (1.26 mmol/l). The ALP was elevated at
1350 IU/l and the PTH level was measured 3 days later
at 455 ng/l. The 25OHD level was slightly low at
9 nmol/l while the 1,25D was normal (60 pmol/l). The
ALP level rose steadily (from 1350 IU/l to 2593 IU/l)
and vitamin D therapy (3600 U ergocalciferol/day) was
initiated at 1 month. At that time, his calcium and
phosphate levels remained normal (2.45 mmol/l and
1.55 mmol/l respectively). Within a week of vitamin D
therapy, the PTH level had begun to drop and the ALP
level started decreasing after 2 weeks of therapy. The last
measurement of ALP at 4 months of age was 1881 IU/l.
Fig. 5 PA ﬁlm of the chest (case 1) at 4 months shows the greatly
expanded ribs, typical of ML II
Fig. 4 X-ray ﬁlms of the left femur demonstrating the changes over
the ﬁrst 4 months of life in case 1. A 4 days: the femur is osteopenic
and bent with a sleeve of calciﬁcation around an inner bone. The
area proximal to the distal femoral metaphysis appears unossiﬁed
and the metaphysis itself is frayed and expanded, as is the proximal
tibial metaphysis. B 2 weeks: the bend in the femur is even more
acute at this age with worsening of the metaphyseal changes. C 6
weeks: with introduction of vitamin D therapy, the osteopenia has
lessened, the metaphysis is less irregular, and periosteal cloaking is
resolving. D 4 months: the metaphyseal changes have resolved and
the texture of the bone is improved. A degree of diaphyseal
expansion remains, as is typical for severe dysostosis multiplex in
ML II
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X-ray ﬁlms at that age showed some resolution of the
osteopenia but periosteal reaction was still present.
Unfortunately, the child was lost to further follow-up
when the family moved back to Pakistan.
The diagnosis of ML II had been conﬁrmed at 2
weeks of age by assay of enzymes in serum: arylsulfatase
A 1767 nmol/h per ml (0 nmol/h/ml in control) and
total hexosaminidase 23880 nmol/h per ml. A skin
biopsy was done and assay of enzyme activities in
ﬁbroblasts showed a drastic reduction in substrate
hydrolysed compared to controls and characteristic
inclusions were seen on light microscopy, further
conﬁrming the diagnosis of ML II.
Case 3
The patient was born to a 28-year-old G4P3L1 mother.
The parents were non-consanguineous and of Hispanic
descent. The parents previously had one infant who died
in rural Mexico after being born at 24 weeks gestation
and another infant who died in Mexico at 9 months of
age from ‘‘brittle bone’’ disease. This fourth child of the
couple was born by caesarean section at 29 weeks
gestation because of fetal bradycardia. The Apgar scores
were 6 at 1 min and 7 at 5 min. Intubation, along with
surfactant administration, was required for treatment of
respiratory distress and the child remained intubated for
the 1st month of life. The admitting physical examina-
tion revealed a birth weight of 941 g (3rd percentile) and
the head circumference was 25.5 cm (<50th percentile).
On admission, a chest X-ray ﬁlm showed a granular
pattern to the lung parenchyma consistent with respi-
ratory distress syndrome. Skeletal X-ray ﬁlms showed
generalised osteopenia. The periosteal cloaking was
most dramatic in the humeri producing an almost bone
within bone appearance and cloaking was also evident in
both femurs and the forearms (Fig. 7). In addition, 11
paired ribs were noted and there was coccygeal stippling.
On the 1st day of life, serum phosphate was
2.2 mmol/l, total calcium was 1.9 mmol/l, and the ALP
was 498 IU/l. A renal ultrasound was normal with no
evidence of nephrocalcinosis. On day 26, the 25OHD
was 25.0 nmol/l and 1,25D was 149 pmol/l. A PTH level
was markedly elevated at 651 ng/l and at 2 months
remained elevated (358 ng/l). ALP continued to rise and
was 1015 IU/l at 1 month. At this time, the serum
calcium and phosphate remained in the normal range at
2.2 mmol/l and 1.9 mmol/l respectively. Both parents
were evaluated when the baby was 6 weeks old and their
Fig. 6 X-ray ﬁlm of the distal
tibia and ﬁbula of case 2
demonstrating metaphyseal
expansion and fraying typical of
hyperparathyroidism as well as
the bilateral tarsal stippling
which is frequently seen in ML
II [1, 7,32]
Fig. 7 X-ray ﬁlm of the humeri
and upper chest of case 3 at 8
days. Both humeri have a
cloaked appearance (bone
within a sleeve of bone) and the
ribs are osteopenic and
somewhat broadened
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PTH levels were normal. The mother’s calcium was
2.3 mmol/l and phosphate 1.1 mmol/l. The father’s
calcium was 2.3 mmol/l and phosphate was 1.6 mmol/l.
The infant developed dysmorphic facial features with
marked gingival hypertrophy and enzyme studies in
cultured ﬁbroblasts conﬁrmed the diagnosis of ML II.
Alpha-mannosidase activity was 0.65 nmol substrate
hydrolyzed/h per mg protein (control 38.4 nmol/h/mg),
beta-galactosidase activity was 2.2 nmol substrate hy-
drolysed/h per mg protein (control 254 nmol/h/mg), and
beta-hexosaminidase activity was 199 nmol substrate
hydrolysed/h per mg protein (control 3094 nmol/h/mg).
In addition, cultured cells were engorged with large
dense lysosomes consistent with ML II.
The infant was discharged home at 3.5 months
requiring supplemental oxygen and gastrostomy tube
feedings. He was not treated with vitamin D or calcium
supplements. At 4 months, the calcium was 2.3 mmol/l,
phosphate was 2.0 mmol/l and ALP was further ele-
vated at 1289 IU/l while intact PTH was 103 ng/l. At 16
months, a repeat ALP was normal (160 IU/l) and the rib
fractures had healed. Follow-up at 20 months showed
that the radiological features of hyperparathyroidism
had resolved as had the biochemical features (ALP
503 IU/l, PTH 58 ng/l, total calcium 2.3 mmol/l).
Discussion
Review of the literature shows there is a subset of pa-
tients with ML II who present in the neonatal period
with features of ‘‘metabolic’’ bone disease rather than
with signs of dysostosis multiplex [1, 3, 4, 5, 7, 9, 15, 17,
21, 23, 31, 32,34]. Indeed, the presenting feature of our
patients was bone disease with increased serum PTH and
ALP activity, but normal serum calcium concentrations.
This ‘secondary’ hyperparathyroidism resolved sponta-
neously or with supplemental vitamin D and calcium.
All three children developed typical clinical and radio-
logical features of ML II later in the course, and only
then was the conﬁrmation of the underlying disorder
straightforward.
While several authors have noted a hyperparathyroid-
like or rickets-like phenotype at birth inML II, there have
been limited investigations of this early bone disease,
perhaps because of the lack of hypocalcaemia and the
lethal nature of ML II. In some cases, an initial diagnosis
of osteogenesis imperfecta is suspected because of severe
osteopenia, fractures and long bone deformity [15, 17, 22,
23,31]. In a review of the radiology in 12 patients, Paz-
zaglia et al. identiﬁed two groups [23]. The ﬁrst consisted
of seven patients presenting at birth or in the early neo-
natal period with radiological features of hyperparathy-
roidism. Four of their cases had elevated ALP and
histological examination of the bone, available in two
cases, was consistent with rickets and/or hyperparathy-
roidism [23,24]. In their series, the authors noted that the
neonatal presentation was associated with an unfavour-
able course and early lethality. Review of other cases with
perinatalmetabolic bonedisease supports this conclusion,
as most infants with neonatal manifestations of ML II
have died before the 2nd year of life [5, 15, 21, 32,34],
rather than the more usual life expectancy of 3 to 8 years
[17,20]. After birth, the extracellular calcium concentra-
tion is meticulously controlled by a G-protein coupled
calcium-sensing receptor (CASR) in the parathyroid
gland [8,25]. Heterozygosity for an inactivating mutation
of the CASR gene causes hypocalciuric hypercalcaemia in
both mice and men (OMIM 145980) [8,25] and in some
instances (e.g., a mutation-carrying fetus in a normo-
calcemic mother) can lead to neonatal severe hyperpara-
thyroidism (NSPHT) (OMIM 239200) [2]. NSHPT can
also be caused by homozygous inactivating mutations of
the CASR [6]. The radiological phenotype of NSHPT is
very similar to that seen in severe neonatal ML II; how-
ever, the two disorders are readily distinguishable at a
biochemical level, because the elevated PTH concentra-
tions in NSHPT are matched by reactively high serum
calcium levels [2,6]. In contrast, the extracellular calcium
concentrations are normal in ML II cases with elevated
PTH, supporting the notion that coupling between cal-
cium and PTH is unaﬀected, and that the parathyroid
gland, through its intact CASRs, is responding to severe
prenatal calcium deﬁciency by secreting PTH in order to
maintain a normal extracellular calcium concentration.
This would explain the ﬁnding that the metabolic bone
disease resolves postnatally either spontaneously or per-
haps more rapidly following treatment with vitamin D
and calcium [22, 28].
Evidence from mouse models has shown that PTH
has a role in fetal calcium homeostasis, but it is shared
with its oncofetal homologue, parathyroid hormone-re-
lated peptide (PTHrP) [12,14]. In utero, active calcium
transport across the placenta accelerates in the third
trimester as the growing skeleton calciﬁes and the fetus
has higher serum calcium than the mother, despite eﬃ-
cient transfer from the extracellular compartment into
mineralising bone [11]. Homozygous Hoxa-3 null mice
are aparathyroid and have undetectable levels of PTH.
These mice are hypocalcaemic and hyperphosphataemic
but have a normal rate of placental calcium transfer [13].
Interestingly, fetal mice who are homozygous null for
the PTHrP gene are hypocalcaemic and unable to
maintain the maternal-fetal calcium gradient, due to
reduced transplacental calcium transport [11]. These
mice have a skeletal dysplasia with moderately short-
ened long bones in utero and they do not survive the
neonatal period [10]. The model to account for the
observations in fetal mice with diﬀerent gene deletions,
is that fetal CASR regulates serum calcium via PTH
levels, while a diﬀerent receptor in the placenta is likely
responsible for coupling the endocrine signal of fetal
PTHrP to the trans-placental transport process [13,14].
Deﬁcient transplacental calcium transport can lead to
hyperparathyroidism in the fetus; an infant born to a
mother with idiopathic hypoparathyroidism and fre-
quent hypocalcaemia had low normal calcium but
markedly increased PTH with demineralisation of the
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skeleton and metaphyseal changes [18]. In MLII, the
placenta is aﬀected [26], and histological examination
shows generalised vacuolisation of the cytoplasm (the
‘inclusions’ of I-cell disease) in the syncytiotrophoblastic
layer where active transplacental transport is regulated
[1,26]. It is reasonable, therefore, to speculate that the
inclusion process interferes with appropriate localisation
or action of PTHrP and/or its receptor(s) and diminishes
placental calcium transfer with concordant increase in
PTH secretion to maintain extracellular calcium at the
expense of the skeleton.
Recognising ML II as a possible cause of neonatal
hyperparathyroidism is important because although the
osteopenia may improve, the overall prognosis is deter-
mined by the underlying lysosomal disorder. In the new-
born, the radiological features of hyperparathyroidism
may be prominent and obscure the more subtle signs of
ML II. In 1993, Shohat et al. [30], reported an infant born
at 28 weeks who died at 30 min of age and described her
condition as a ‘‘new epiphyseal stippling syndrome with
osteoclastic hyperplasia’’ and suggested the namePacman
dysplasia. Since that time a further three fetuses have been
reported as having Pacman dysplasia (OMIM 167220)
[19,33]. While it was recognised that the radiological
features (including fetal stippling)were similar toML II, it
was felt that the histology was not consistent with that
disorder since it consisted of excessive bone resorption
with numerous osteoclasts including giantmultinucleated
ones [19, 30,33]. However, that histology is entirely con-
sistent with hyperparathyroidism and in the light of our
observations, it seems most likely that Pacman dysplasia
is actually fetal/neonatal MLII with secondary hyper-
parathyroidism. Indeed, after we had suggested this
hypothesis at the 2003 ISDS meeting, a family whose ﬁrst
fetus had been diagnosed with Pacman dysplasia [19] had
a second child who had ML II [29], conﬁrming this
hypothesis.
ML II can present in the neonatal period with severe
secondary hyperparathyroidism, possibly as a result of
impaired transplacental calcium transport. While ML II
remains a rare recessive condition, careful observation
of the phenotype may provide us with insights into the
normal process of fetal accretion of calcium and skeletal
mineralisation. Clinicians should be aware that when a
fetus or infant presents with shortened and bowed
limbs and osteopenia, hyperparathyroidism secondary
to severe ML II is a diagnostic possibility.
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